Aspirin for the Prevention of Cardiovascular Disease and Colorectal Cancer: New Recommendations from the USPSTF
Owens, D.K.
American Family Physician 95(4): 222-223
2017
ISSN/ISBN: 0002-838X PMID: 28290628 Document Number: 692279
Document emailed within 1 workday
Related Documents
Smith, D.K.; Demetriou, T.; Weber, C. 2019: Aspirin for primary prevention: USPSTF recommendations for CVD and colorectal cancer Journal of Family Practice 68(3): 146-151Selak, V.; Jackson, R.; Poppe, K.; Kerr, A.; Wells, S. 2018: Are the benefits of aspirin likely to exceed the risk of major bleeds among people in whom aspirin is recommended for the primary prevention of cardiovascular disease? New Zealand Medical Journal 131(1484): 19-25
Nakamura Masato 2015: Aspirin for the prevention of colorectal cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 42(11): 1357-1362
Miser, W.Fred. 2011: Appropriate aspirin use for primary prevention of cardiovascular disease American Family Physician 83(12): 1380-1386
Campos-Outcalt, D. 2010: USPSTF recommendations you may have missed amid the breast cancer controversy Journal of Family Practice 59(5): 276-280
De Caterina, R. 2003: Low-dose aspirin in the primary prevention of cardiovascular disease: how to balance the benefits and the risks Italian Heart Journal: Official Journal of the Italian Federation of Cardiology 4(4): 228-231
Campos-Outcalt, D. 2016: 8 USPSTF recommendations FPs need to know about Journal of Family Practice 65(5): 338-341
Hiatt, W.R. 2008: Aspirin for prevention of cardiovascular events Bmj 337: A1806
Kulbertus, H. 2005: Aspirin and cardiovascular prevention: last minute information Revue Medicale de Liege 60(3): 198-200
Schuler, M. 1996: Aspirin and the risk of colorectal cancer in women New England Journal of Medicine 334(2): 121-122
Guo, Y.F. 2019: Effects of aspirin on primary prevention of cardiovascular events in patients with hypertension Zhonghua Nei Ke Za Zhi 58(4): 249-251
Maciá Bobes, C.; Ronzón Fernández, Aánzazu.; Fernández García, E. 2007: Primary prevention with aspirin for cardiovascular diseases in diabetic patients. What evidence supports the criteria of the ADA? Atencion Primaria 39(3): 163-164
1999: From the Centers for Disease Control and Prevention. Screening for colorectal cancer--United States, 1997 JAMA 281(17): 1581-1582
Rus, H.; Niculescu, F.I. 1997: Inflammation, aspirin, and the risk of cardiovascular disease New England Journal of Medicine 337(6): 423; Author Reply 423-424
Farmer, K.C.; Goulston, K.; Macrae, F. 1993: Aspirin and non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer Medical Journal of Australia 159(10): 649-650
Iavelov, I.S. 2006: Aspirin in primary prevention of cardiovascular events in women and men (a meta-analysis of randomized controlled trials) Kardiologiia 46(3): 75-76
Benamouzig, R. 1998: Do aspirin or nonsteroidal anti-inflammatory drugs decrease the risk of colorectal cancer? Gastroenterologie Clinique et Biologique 22(3 Suppl): S22-S27
Pahkala, K.; Niinikoski, H.; Raitakari, O. 2014: Prevention of cardiovascular diseases--the most recent recommendations from the United States Duodecim; Laaketieteellinen Aikakauskirja 130(8): 778-784
2001: From the Centers for Disease Control and Prevention. Trends in screening for colorectal cancer--United States, 1997 and 1999 JAMA 285(12): 1570-1571
1996: From the Centers for Disease Control and Prevention. Screening for colorectal cancer--United States, 1992-1993, and new guidelines JAMA 275(11): 830-831